Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review
- 10 December 2021
- journal article
- review article
- Published by Edizioni Internazionali srl, Divisione EDIMES Edizioni Medico-Scientifiche in Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
- Vol. 29 (4) , 495-503
Abstract
To date, only corticosteroids and interleukin-6 (IL-6) inhibitors have been shown to reduce mortality of hospitalized patients with COVID-19. In this literature review, we aimed to summarize infection risk of IL inhibitors, with or without the use of corticosteroids, used to treat hospitalized patients with COVID-19. A literature search was conducted using the following evidence-based medicine reviews: Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Embase; Ovid Medline; and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions 1946 to April 28, 2021. All relevant articles were identified using the search terms COVID-19 or SARS-coronavirus-2, infections, interleukins, inpatients, adults, and i ncidence. We identified 36 studies of which 2 were meta-analyses, 5 were randomized controlled trials, 9 were prospective studies, and 20 were retrospective studies. When anakinra was compared with control, 2 studies reported an increased risk of infection, and 3 studies reported a similar or decreased incidence of infection. Canakinumab had a lower associated incidence of infection compared with placebo in one study. When sarilumab was compared with placebo, one study reported an increased risk of infection. Nine studies comparing tocilizumab with placebo reported decreased or no difference in infection risk (odds ratio [OR] for the studies ranged from 0.39-1.21). Fourteen studies comparing tocilizumab with placebo reported an increased risk of infection, ranging from 9.1% to 63.0% (OR for the studies ranged from 1.85-5.04). Infection most commonly presented as bacteremia. Of the 6 studies comparing tocilizumab and corticosteroid use with placebo, 4 reported a nonsignificant increase toward corticosteroids being associated with bacterial infections (OR ranged from 2.76-3.8), and 2 studies reported no increased association with a higher infection risk. Our literature review showed mixed results with variable significance for the association of IL-6 inhibitors with risk of infections in patients with COVID-19.Keywords
This publication has 50 references indexed in Scilit:
- The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor systemCytokine & Growth Factor Reviews, 2020
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Pathogenesis of COVID-19 from a cell biology perspectiveEuropean Respiratory Journal, 2020
- Guide to Understanding the 2019 Novel CoronavirusMayo Clinic Proceedings, 2020
- A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman DiseaseClinical Cancer Research, 2013
- [Side effects and contraindications for biological therapy in inflammatory bowel disease].2013
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnnals of the Rheumatic Diseases, 2008
- Evolving functions of endothelial cells in inflammationNature Reviews Immunology, 2007
- Safety of extended treatment with anakinra in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trialArthritis & Rheumatism, 2003